Dose | Systemic Exposure | Liver Tissue Exposure | Inlet to Liver | Reported IC50 | Reference | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cmax | AUC | C8h | Iin,max,u | OATP1B1 | OATP1B3 | MRP2 | BCRP | MDR1 | |||
mg/kg | μmol/l | μmol·h/l | μmol/kg tissue | μmol/l | μmol/l | ||||||
PXB mice | 10 | 0.131 | 0.292 | 1.07 | 0.29–0.94 | ||||||
50 | 0.349 | 1.02 | 5.89 | 1.4–4.7 | 0.15 | 0.68 | 9.3 | 1.5 | 1.7 | ||
SCID mice | 10 | 0.402 | 1.20 | 4.95 | 0.36–0.96 | ||||||
50 | 1.58 | 5.25 | 30.0 | 1.5–4.8 | Yoshida et al. (2012) |
C8h, corresponding to liver concentrations 8 hours after oral administration of rosuvastatin; MDR1, multidrug resistance protein 1.